Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 93

1.

Multi-drug-resistant cells enriched from chronic myeloid leukemia cells by Doxorubicin possess tumor-initiating-cell properties.

Xin H, Kong Y, Jiang X, Wang K, Qin X, Miao ZH, Zhu Y, Tan W.

J Pharmacol Sci. 2013;122(4):299-304. Epub 2013 Aug 1.

2.

Influence of adriamycin on changes in Nanog, Oct-4, Sox2, ARID1 and Wnt5b expression in liver cancer stem cells.

Sun D, Qin L, Xu Y, Liu JX, Tian LP, Qian HX.

World J Gastroenterol. 2014 Jun 14;20(22):6974-80. doi: 10.3748/wjg.v20.i22.6974.

3.

Snail1 induces epithelial-to-mesenchymal transition and tumor initiating stem cell characteristics.

Dang H, Ding W, Emerson D, Rountree CB.

BMC Cancer. 2011 Sep 19;11:396. doi: 10.1186/1471-2407-11-396.

4.
5.

JNK is required for maintaining the tumor-initiating cell-like properties of acquired chemoresistant human cancer cells.

Liu Y, Zhang X, Wang J, Yang J, Tan WF.

Acta Pharmacol Sin. 2015 Sep;36(9):1099-106. doi: 10.1038/aps.2015.58. Epub 2015 Aug 3.

6.

Reversal effect of a macrocyclic bisbibenzyl plagiochin E on multidrug resistance in adriamycin-resistant K562/A02 cells.

Shi YQ, Qu XJ, Liao YX, Xie CF, Cheng YN, Li S, Lou HX.

Eur J Pharmacol. 2008 Apr 14;584(1):66-71. doi: 10.1016/j.ejphar.2008.01.039. Epub 2008 Feb 5.

PMID:
18304528
7.

Bmi1 regulates self-renewal and epithelial to mesenchymal transition in breast cancer cells through Nanog.

Paranjape AN, Balaji SA, Mandal T, Krushik EV, Nagaraj P, Mukherjee G, Rangarajan A.

BMC Cancer. 2014 Oct 28;14:785. doi: 10.1186/1471-2407-14-785.

8.

Twist1-mediated adriamycin-induced epithelial-mesenchymal transition relates to multidrug resistance and invasive potential in breast cancer cells.

Li QQ, Xu JD, Wang WJ, Cao XX, Chen Q, Tang F, Chen ZQ, Liu XP, Xu ZD.

Clin Cancer Res. 2009 Apr 15;15(8):2657-65. doi: 10.1158/1078-0432.CCR-08-2372. Epub 2009 Mar 31.

9.

Relationships between multidrug resistance (MDR) and stem cell markers in human chronic myeloid leukemia cell lines.

Marques DS, Sandrini JZ, Boyle RT, Marins LF, Trindade GS.

Leuk Res. 2010 Jun;34(6):757-62. doi: 10.1016/j.leukres.2009.11.004. Epub 2009 Dec 6.

PMID:
19969351
10.

CD133+ subpopulation of the HT1080 human fibrosarcoma cell line exhibits cancer stem-like characteristics.

Feng BH, Liu AG, Gu WG, Deng L, Cheng XG, Tong TJ, Zhang HZ.

Oncol Rep. 2013 Aug;30(2):815-23. doi: 10.3892/or.2013.2486. Epub 2013 May 23.

PMID:
23708735
11.

Ligustrazine derivate DLJ14 reduces multidrug resistance of K562/A02 cells by modulating GSTĪ€ activity.

Song YN, Guo XL, Zheng BB, Liu XY, Dong X, Yu LG, Cheng YN.

Toxicol In Vitro. 2011 Jun;25(4):937-43. doi: 10.1016/j.tiv.2011.03.002. Epub 2011 Mar 21.

PMID:
21402141
12.

Down-regulation of mitochondrial ATPase by hypermethylation mechanism in chronic myeloid leukemia is associated with multidrug resistance.

Li RJ, Zhang GS, Chen YH, Zhu JF, Lu QJ, Gong FJ, Kuang WY.

Ann Oncol. 2010 Jul;21(7):1506-14. doi: 10.1093/annonc/mdp569. Epub 2009 Dec 27.

PMID:
20038517
13.

Reversal of p-glycoprotein-mediated multidrug resistance by macrocyclic bisbibenzyl derivatives in adriamycin-resistant human myelogenous leukemia (K562/A02) cells.

Li X, Sun B, Zhu CJ, Yuan HQ, Shi YQ, Gao J, Li SJ, Lou HX.

Toxicol In Vitro. 2009 Feb;23(1):29-36. doi: 10.1016/j.tiv.2008.09.015. Epub 2008 Oct 1.

PMID:
18938236
14.

Twist1 and Snail link Hedgehog signaling to tumor-initiating cell-like properties and acquired chemoresistance independently of ABC transporters.

Kong Y, Peng Y, Liu Y, Xin H, Zhan X, Tan W.

Stem Cells. 2015 Apr;33(4):1063-74. doi: 10.1002/stem.1955.

15.

Reversal effect of substituted 1,3-dimethyl-1H-quinoxalin-2-ones on multidrug resistance in adriamycin-resistant K562/A02 cells.

Sun LR, Li X, Cheng YN, Yuan HY, Chen MH, Tang W, Ward SG, Qu XJ.

Biomed Pharmacother. 2009 Mar;63(3):202-8. doi: 10.1016/j.biopha.2008.07.090. Epub 2008 Aug 28.

PMID:
18818047
16.

Effect of magnetic nanoparticles of Fe3O4 and 5-bromotetrandrine on reversal of multidrug resistance in K562/A02 leukemic cells.

Cheng J, Wu W, Chen BA, Gao F, Xu W, Gao C, Ding J, Sun Y, Song H, Bao W, Sun X, Xu C, Chen W, Chen N, Liu L, Xia G, Li X, Wang X.

Int J Nanomedicine. 2009;4:209-16. Epub 2009 Oct 19.

17.

Imatinib mesylate (STI571) abrogates the resistance to doxorubicin in human K562 chronic myeloid leukemia cells by inhibition of BCR/ABL kinase-mediated DNA repair.

Majsterek I, Sliwinski T, Poplawski T, Pytel D, Kowalski M, Slupianek A, Skorski T, Blasiak J.

Mutat Res. 2006 Jan 31;603(1):74-82. Epub 2006 Jan 4.

PMID:
16388976
18.

Evi1 defines leukemia-initiating capacity and tyrosine kinase inhibitor resistance in chronic myeloid leukemia.

Sato T, Goyama S, Kataoka K, Nasu R, Tsuruta-Kishino T, Kagoya Y, Nukina A, Kumagai K, Kubota N, Nakagawa M, Arai S, Yoshimi A, Honda H, Kadowaki T, Kurokawa M.

Oncogene. 2014 Oct 16;33(42):5028-38. doi: 10.1038/onc.2014.108. Epub 2014 Apr 21.

19.

Substituted tetrahydroisoquinoline compound B3 inhibited P-glycoprotein-mediated multidrug resistance in-vitro and in-vivo.

Fang W, Li Y, Cai Y, Kang K, Yan F, Liu G, Huang W.

J Pharm Pharmacol. 2007 Dec;59(12):1649-55.

PMID:
18053326
20.

Sphere-forming stem-like cell populations with drug resistance in human sarcoma cell lines.

Fujii H, Honoki K, Tsujiuchi T, Kido A, Yoshitani K, Takakura Y.

Int J Oncol. 2009 May;34(5):1381-6.

PMID:
19360350

Supplemental Content

Support Center